Giorgio Ammerata

Dr. Giorgio Ammerata

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2017 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
FUFrancesco Ursini
Francesco Ursini
EREmilio Russo
Emilio Russo
DMDaniele Mauro
Daniele Mauro
LALudovico Abenavoli
Ludovico Abenavoli
Giorgio AmmerataGiorgio Ammerata
Giorgio Ammerata
SDSalvatore D'Angelo
Salvatore D'Angelo

1 August 2018 in Reviews on Recent Clinical Trials
Verified
Journal Article
Closed access
PDF file
FUFrancesco Ursini
Francesco Ursini
SDSalvatore D`angelo
Salvatore D`angelo
EREmilio Russo
Emilio Russo
Giorgio AmmerataGiorgio Ammerata
Giorgio Ammerata
LALudovico Abenavoli
Ludovico Abenavoli
GSGiovambattista De Sarro
Giovambattista De Sarro
Background: Recent evidence demonstrated a potential role of complement C3 as a candidate biomarker of cardiometabolic risk in the general population. Objective: Aim of the present study was to investigate the correlation between complement C3 levels and comorbid Type 2 Diabetes (T2DM) in Rheumatoid Arthritis (RA) patients. Methods: For the present study, 40 consecutive diabetic RA patients (RA/T2DM+ group) and 80 consecutive RA patients without diabetes (RA/T2DM- group) were recruited. Results: Patients in the RA/T2DM+ group were significantly older (p < 0.0001), had a longer RA duration (p < 0.0001) and higher disease activity (p = 0.006) compared to controls. Moreover, patients in the RA/T2DM+ group had significantly higher levels of ESR (p < 0.0001), CRP (p < 0.0001) and complement C3 (p < 0.0001). A logistic regression model was built to ascertain the effect of selected variables (age, RA duration, BMI, ESR, C3, lnCRP, corticosteroid use) on the likelihood that patients have T2DM. Longer RA duration, ESR and C3 were associated with an increased likelihood of being classified as T2DM. Finally, we built ROC curves to evaluate the predictivity of RA duration, complement C3 and the combination of both variables on the likelihood of being diagnosed with T2DM. The area under the ROC curve was 0.79 (p < 0.0001) for RA duration, 0.71 (p < 0.0001) for complement C3 and 0.89 (p < 0.0001) for the combination of both variables. Conclusion: According to our data complement C3 levels can predict the presence of T2DM in RA patients.

26 October 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
Giorgio AmmerataGiorgio Ammerata
Giorgio Ammerata
RFRosalinda Filippo
Rosalinda Filippo
Carmelo LafaceCarmelo Laface
Carmelo Laface
RMRiccardo Memeo
Riccardo Memeo
Leonardo SolainiLeonardo Solaini
Leonardo Solaini
MAMichele Ammendola
Michele Ammendola
The pursuit of this paper is to collect principal reviews and systematic reviews about hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) used in colorectal cancer (CRC). We focus on principal biological aspects of CRC, hyperthermia effects, and surgical procedures. We searched PubMed/MEDLINE for the principal reviews and systematic reviews published from 2010 to 2021 regarding the bimodal treatment (CRS + HIPEC) against local and advanced CRC. In the literature, from several studies, it seems that the efficacy of bimodal treatment with an accurate CRS can extend overall survival. Despite these studies, there are not still any straight guidelines more detailed and scheduled about the use of combined treatment in patients with CRC. Even if the concept is still not very clear and shared, after a careful evaluation of the published data, and after some technical and pathophysiological descriptions, we concluded that it is possible to improve the overall survival and quality of life and to reduce the tumor relapse in patients affected by locally advanced (pT4) CRC with peritoneal metastases.

10 December 2020 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MAMichele Ammendola
Michele Ammendola
MRMichele Ruggiero
Michele Ruggiero
CTCarlo Talarico
Carlo Talarico
RMRiccardo Memeo
Riccardo Memeo
Giorgio AmmerataGiorgio Ammerata
Giorgio Ammerata
GCGiuseppe Currò
Giuseppe Currò
Background: Colorectal cancer (CRC) is the most common tumor of the gastrointestinal tract. Anastomotic leak (AL) and prolonged postoperative ileus (PPOI) are two important complications of colorectal surgery. In this observational retrospective study, we evaluated the positive effects of transanal tube No Coil®in patients with CRC undergoing low anterior resection (LAR) and left hemicolectomy (LC).Methods: Thirty-eight cases and forty controls resulted eligible for the final sample. No Coil®placement (SapiMed Spa, Alessandria, Italy) was considered an inclusion criteria for the case group. No Coil®was placed immediately after the end of surgical treatment.Results: PPOI was significantly more frequent in the control group. AL was evident in 1 patient (2.6%) of cases and 3 patients (7.5%) of controls. No statistical difference was found in AL occurrence between groups. POI days and AL resulted associated with hospital stay. POI days were negatively associated with No Coil placement and positively with AL.Conclusion: With our preliminary data, we suggest that No Coil®placement can be considered as a valuable procedure assisting colorectal surgery, but further studies are required to confirm and enlarge actual evidence.

3 June 2017 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
FUFrancesco Ursini
Francesco Ursini
SDSalvatore D'Angelo
Salvatore D'Angelo
APAngela Padula
Angela Padula
PLPietro Leccese
Pietro Leccese
GAGiuseppina Abignano
Giuseppina Abignano
IOIgnazio Olivieri
Ignazio Olivieri

13 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
GSGiuseppe Sena
Giuseppe Sena
GCGiuseppe Currò
Giuseppe Currò
GVGiuseppina Vescio
Giuseppina Vescio
Giorgio AmmerataGiorgio Ammerata
Giorgio Ammerata
AAAngela Amaddeo
Angela Amaddeo
ARAntonia Rizzuto
Antonia Rizzuto
Introduction: There is no consensus on managing non-functioning pancreatic neuroendocrine tumors smaller than 2 cm (NF-PANNETs < 2 cm). Therefore, their treatment remains controversial. The aim of this study, by literature review and meta-analysis, is to establish the best management of NF-PANNETs < 2 cm based on overall survival (OS) and cancer-specific survival (CSS). Materials and Methods: An extensive online search was conducted using the MEDLINE, EMBASE, Google Scholar, Scopus, Web of Science, and Cochrane Central databases. All retrospective and prospective studies were included in this study, comparing the outcomes of surgical management vs. conservative management in patients with NF-PANNETs < 2 cm. The pooled odds ratio and 95% CI for survival were calculated. Results: Six studies were included in the quantitative analysis, with 2708 patients managed operatively and 985 managed conservatively. A pooled analysis of all the data demonstrated increased OS in patients managed operatively compared with those managed conservatively at five years (OR = 1.77, 95% CI: 0.96 to 2.58; p = 0.002). In contrast, the meta-analysis did not demonstrate increased CSS in patients undergoing surgical resection compared with conservative management (OR = 1.01, 95% CI: −5.25 to 7.27; p = 0.56). Furthermore, analysis demonstrated a high heterogeneity for OS (Q = 43.98, p < 0.001, tau2 = 0.46, I2 = 88.63%) and for CSS (Q = 22.81, p < 0.0001, tau2 = 1.72, I2 = 91.23%). Conclusion: This systematic review and meta-analysis indicated that surgical management of NF-PANNETs < 2 cm improves overall survival (OS) but does not significantly enhance cancer-specific survival (CSS). There is variability in outcomes among studies, and while surgery may help some patients, the lack of clear CSS benefits and associated risks call for individualized decision-making. Therefore, a conservative approach with active surveillance may be more suitable for low-risk patients.